To further investigate the prognostic value and clinical outcomes of IKZF3 amplification in GC, Kaplan–Meier analysis was performed with the results that compared with the group without IKZF3 amplification (n = 376, median DFS, 50.9 months; median OS, 53.8 months), cases with IKZF3 amplification (n = 28) gained significant worse survival with a median DFS 39.7 months (P = 0.014) and median OS 45.7 months (P = 0.018) respectively (Fig. 1G-H). The gene discussed is IKZF3; the disease is gastric cancer.